Alternative Stent Supply Agreement Violated By Medinol - BSX Countersuit
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is charging Israeli stent partner Medinol with violating their supply agreement by failing to provide chemical etching services that would benefit an alternative stent line sanctioned by the deal.
You may also be interested in...
Boston Scientific Ramping Up Internal R&D; Medinol Claims Infringement
Boston Scientific's R&D spending is expected to jump roughly 16% to $230 mil. in 2001, reflecting the firm's increased commitment to in-house innovation as opposed to relying primarily on acquisitions to build its product pipeline.
Boston Scientific Express Stent Potentially Threatened By Medinol Lawsuit
Boston Scientific's strategy to rely on its internally developed Express coronary stent platform as a viable alternative to a troubled relationship with stent partner Medinol may be jeopardized by the Israeli firm's April 5 lawsuit alleging that the Express R&D initiative constituted breach of contract by Boston Scientific.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.